Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Awards for blood glucose monitoring equipment

GlySure : 02 October, 2013  (Company News)
New product and small business of the year awards given to GlySure for the company's work on coninuous blood glucose monitoring systems
Awards for blood glucose monitoring equipment


GlySure, a developer of in-hospital continuous blood glucose monitoring (CBGM) systems, has won two major awards in the 2013 BIG (Business Intelligence Group) Awards for Business.



BIG has selected GlySure as Small Business of the Year and it also won New Product of the Year for its CBGM technology.



Business Intelligence Group’s BIG Awards specialize in recognizing top performing companies and organizations. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains, and rewards companies whose achievements stand above those of their peers.



“Glysure's mission and product to help control glucose levels in real time is clearly in demand,” said Dawn Fordyce of the Business Intelligence Group. “With so much at stake, Glysure's continuous blood glucose monitoring system will surely save countless lives and healthcare costs."



Over two years of human use trials in over 150 intensive care unit (ICU) patients have proven that GlySure’s CBGM technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across three-to-five days of a patient’s stay, which is key to improving outcomes and reducing costs in the ICU. GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.



“It is a great honour to be recognized by the Business Intelligence Group,” said GlySure CEO Chris Jones. “This industry recognition validates the tremendous momentum we’ve achieved to date in delivering on the promise of Tight Glycemic Control.”


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo